PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsFosaprepitant dimeglumine
Fosaprepitant dimeglumine
Emend, Focinvez, Fosaprepitant Dimeglumine, Ivemend (fosaprepitant dimeglumine) is a small molecule pharmaceutical. Fosaprepitant dimeglumine was first approved as Ivemend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Emend, Focinvez, Fosaprepitant dimeglumine (discontinued: Emend, Fosaprepitant dimeglumine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosaprepitant dimeglumine
Tradename
Company
Number
Date
Products
EMENDMerck & CoN-022023 RX2010-11-12
1 products, RLD, RS
FOCINVEZSteriScienceN-216686 RX2023-08-22
1 products, RLD, RS
FOSAPREPITANT DIMEGLUMINETevaN-210064 RX2019-09-05
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
emendNew Drug Application2022-05-04
focinvezNew Drug Application2025-06-12
fosaprepitantANDA2024-12-29
fosaprepitant dimeglumineANDA2024-08-15
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
FOSAPREPITANT DIMEGLUMINE, EMEND, MERCK AND CO INC
2025-05-02D-186
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A04: Antiemetics and antinauseants
— A04A: Antiemetics and antinauseants
— A04AD: Other antiemetics in atc
— A04AD12: Aprepitant
HCPCS
No data
Clinical
Clinical Trials
126 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VomitingD014839—R11.182219181580
NauseaD009325—R11.042117141670
Postoperative nausea and vomitingD020250EFO_0004888—2349724
NeoplasmsD009369—C803322513
LymphomaD008223—C85.912—136
LeukemiaD007938—C95—2—125
Breast neoplasmsD001943EFO_0003869C501—1114
Ovarian neoplasmsD010051EFO_0003893C56———134
Healthy volunteers/patients———2——1—3
PruritusD011537—L2911—1—3
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DepressionD003863—F33.9——9——9
Major depressive disorderD003865EFO_0003761F22——9——9
Depressive disorderD003866EFO_1002014F32.A——9——9
Multiple myelomaD009101—C90.0111—25
Non-small-cell lung carcinomaD002289——121—14
Plasma cell neoplasmsD054219———11—24
Lung neoplasmsD008175—C34.90—11—13
Female genital neoplasmsD005833————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AlcoholismD000437EFO_0003829F10.1—3———3
CarcinomaD002277—C80.0—2——13
Myelodysplastic syndromesD009190—D46—1——23
PreleukemiaD011289———1——23
SarcomaD012509———1——12
Marijuana abuseD002189EFO_0007191F12—2———2
Myeloid leukemia acuteD015470—C92.0—2———2
Myeloid leukemiaD007951—C92—2———2
Renal cell carcinomaD002292EFO_0000376——1———1
MelanomaD008545———1———1
Show 20 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B203————3
Opioid-related disordersD009293EFO_0005611F112————2
Heroin dependenceD006556EFO_0004240—2————2
Non-hodgkin lymphomaD008228—C85.91————1
Substance-related disordersD019966EFO_0003890F131————1
Biological availabilityD001682——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal neoplasmsD005770—C26.9————22
Ovarian epithelial carcinomaD000077216——————22
Myeloproliferative disordersD009196—D47.1————22
PlasmacytomaD010954—C90.3————22
Digestive system neoplasmsD004067——————11
Cognitive dysfunctionD060825—G31.84————11
HypertensionD006973EFO_0000537I10————11
Type 2 diabetes mellitusD003924EFO_0001360E11————11
Diabetes mellitusD003920EFO_0000400E08-E13————11
Drug-related side effects and adverse reactionsD064420—T88.7————11
Show 14 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFosaprepitant dimeglumine
INNaprepitant
Description
Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
Classification
Small molecule
Drug classphosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Identifiers
PDB—
CAS-ID172673-20-0
RxCUI1731071
ChEMBL IDCHEMBL1201782
ChEBI ID64311
PubChem CID219090
DrugBankDB06717
UNII ID6L8OF9XRDC (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Emend – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 95 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
7,529 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use